Quality Control Tests for Packaging & Good Laboratory Practices (GLP)
This unit covers two important areas: (1) Quality control tests for pharmaceutical packaging materials — containers (glass and plastic), rubber closures, and secondary packing materials. Packaging is a critical quality attribute since it protects the product throughout its shelf life. (2) Good Laboratory Practices (GLP) — the quality system for non-clinical safety studies. GLP ensures the quality, reliability, and integrity of data from laboratory studies submitted to regulatory agencies.
Syllabus & Topics
- 1QC Tests for Glass Containers: Glass: most widely used primary container for parenterals, oral liquids, and eye preparations. Types (based on hydrolytic resistance): Type I (Borosilicate — highest resistance, for sensitive parenterals), Type II (Treated soda-lime — surface-treated with sulfur, for most parenterals), Type III (Soda-lime — for oral/topical, NOT for parenterals). Tests: (1) Powdered glass test (USP): crushed glass → autoclave with water → titrate with H₂SO₄ → measures alkali released (Type I: ≤1.0 mL, Type III: ≤8.5 mL of 0.02N H₂SO₄). (2) Water attack test (surface test): fill container with water → autoclave → measure alkali released. (3) Arsenic test: measure arsenic leaching from glass. (4) Light transmission test: for amber/light-resistant containers — measure UV-Vis transmission (must block up to 450 nm). (5) Thermal shock test: sudden temperature change → check for cracking.
- 2QC Tests for Plastic Containers: Plastics: HDPE, LDPE, PP, PET, PVC used as containers for oral, topical, ophthalmic products. Tests (IP/USP): (1) Identification: IR spectroscopy → confirm polymer identity. (2) Transparency/light transmission. (3) Water vapor permeability: weigh container with desiccant, store under controlled humidity, reweigh (measures moisture ingress). (4) Leakage test: fill, close, submerge in colored dye solution under vacuum → check for dye entry. (5) Extractables test: extract with water/suitable solvent → identify/quantify extracted substances (must be within limits — no toxic leachables). (6) Nonvolatile residue: evaporate extract → weigh residue. (7) Buffering capacity: test extract pH change. (8) Heavy metals: extractable heavy metals within limits. (9) Microbial limits: plastic packaging must meet microbiological cleanliness standards.
- 3QC Tests for Rubber Closures: Rubber closures: critical for injectables — must form effective seal with container AND not interact with product. Tests: (1) Fragmentation test: pierce closure with needle through same spot → examine for rubber particles (fragments can contaminate parenteral → embolism risk). Limits specified in pharmacopoeia. (2) Self-sealing test: after needle insertion, closure must reseal — no leakage. (3) Extractables: aqueous, acidic, and alkaline extracts analyzed for: volatile sulfides, non-volatile residue, heavy metals, total reducing sugars, UV absorption. (4) Hardness (Shore A): durometer test. (5) Elasticity (closure integrity): compress → measure recovery. (6) Cytotoxicity/biocompatibility: for parenterals, rubber must not be toxic to cells.
- 4QC Tests for Secondary Packing Materials: Secondary packaging: cartons, labels, leaflets, shippers — provide information and physical protection. Tests for printed packaging (labels, cartons): (1) Print quality: text clarity, color accuracy, barcode readability (verified by barcode scanner). (2) Content verification: active ingredient name, strength, batch number, expiry date, manufacturer — all correct per approved artwork. (3) Adhesion test (for labels): peel test — label must adhere firmly and not come off during handling/storage. (4) Rub resistance: printed text must not smudge (Sutherland rub tester). (5) Dimensions: correct size, fit. (6) Material quality: thickness (micrometer), weight, moisture resistance (Cobb test). Tamper-evident features: verified during inspection. Serialization/track-and-trace codes: verified for accuracy.
- 5GLP – Introduction & Purpose: Good Laboratory Practices (GLP): quality system for non-clinical (animal) safety studies. Purpose: ensure quality, integrity, and reliability of data from safety studies submitted to regulatory agencies for drug/chemical/pesticide approval. Origin: FDA scandal (1970s — Industrial BioTest Labs fabricated data) → FDA promulgated GLP regulations (21 CFR Part 58, 1978). OECD GLP Principles: internationally harmonized framework. Applies to: toxicity studies, carcinogenicity, mutagenicity, teratogenicity, pharmacokinetics, environmental studies. Does NOT apply to: clinical trials (governed by GCP), routine QC testing (governed by GMP/pharmacopoeia).
- 6GLP – Organization & Personnel: Study Director: single point of study control → responsible for overall conduct, interpretation, reporting. Must approve protocol and final report. SOLE responsibility for study integrity. QA Unit (Quality Assurance): INDEPENDENT unit that monitors study conduct for GLP compliance. Conducts inspections of study procedures, data, and facilities. Reports directly to management (NOT to Study Director). Management: ensures GLP compliance, provides resources, appoints Study Director, accepts QA reports. Personnel: must be qualified (education, training, experience) for their roles. Training records maintained. Health monitoring for personnel working with test animals/hazardous chemicals.
- 7GLP – Facilities & Equipment: Facilities: (1) Adequate size and construction for study conduct. (2) Separation of functions: test system (animal) rooms, test article storage, data storage, specimen storage, mixing/preparation rooms. (3) Animal facilities: proper housing (temperature, humidity, light cycle, bedding), separation of species, quarantine area, disease control. (4) Adequate utilities (water, power, ventilation). Equipment: (1) Appropriate design and capacity. (2) Adequately maintained, cleaned, calibrated. (3) SOPs for operation, maintenance, calibration. (4) Calibration records maintained (tractable to national standards). (5) Computerized systems must be validated (data integrity — ALCOA: Attributable, Legible, Contemporaneous, Original, Accurate).
- 8GLP – Testing & Protocol: Test and control articles: (1) Adequately characterized (identity, purity, stability, composition). (2) Storage conditions maintained (temperature, humidity). (3) Stability determined over study duration. (4) Homogeneity verified for mixtures. Protocol: written plan BEFORE study begins, approved by Study Director. Must include: (1) Study title and purpose. (2) Test and control articles (identity, route, dose). (3) Test system (species, strain, number, weight). (4) Study schedule (start, duration, endpoints). (5) Data collection methods. (6) Statistical methods. (7) Records to be maintained. Protocol amendments: any deviation from protocol must be documented, justified, and authorized by Study Director.
- 9GLP – Records, Reports & Disqualification: Final report: Study Director must prepare and sign. Contains: objectives, methods, results, conclusions. All raw data archived. Raw data: any laboratory worksheets, records, notes, exact copies. Must be signed, dated, attributable to person generating data. Data retention: raw data, specimens, protocols, final reports RETAINED for the period specified by regulations (typically 2 years after drug approval, or 5 years after study completion). QA statement: included in final report certifying inspections were conducted and findings reported. Disqualification: regulatory authority (FDA) can disqualify a testing facility for: fraudulent data, repeated GLP violations, inability to conduct studies according to GLP. Consequences: studies from disqualified lab not accepted for regulatory submission.
Learning Objectives
Exam Prep Questions
Q1. Why is GLP needed — isn’t GMP enough?
GMP governs MANUFACTURING of drugs — ensures products are consistently made to quality standards. GLP governs SAFETY TESTING (non-clinical studies) — ensures the data submitted to regulatory agencies to prove a drug is safe is reliable and not fabricated. They serve different purposes: GMP = quality of the PRODUCT, GLP = quality of the SAFETY DATA. A drug can be manufactured to GMP standards but if the safety studies used to approve it were fraudulent (not GLP compliant), patients could be harmed.
Q2. What is the Powdered Glass Test?
The powdered glass test determines the hydrolytic resistance of the ENTIRE glass (not just surface). Glass is crushed to specified particle size (150–850 μm range) → 10 g washed, dried → placed in flask with 50 mL purified water → autoclaved at 121°C for 30 min → cooled → titrated with 0.02N H₂SO₄ using methyl red indicator. The volume of acid consumed indicates alkali released from glass. Lower volume = higher hydrolytic resistance = better glass quality. Used to classify glass types (Type I ≤1.0 mL, Type III ≤8.5 mL).
Q3. What does ALCOA mean in data integrity?
ALCOA is the standard for data integrity in regulated environments (GLP, GMP, GCP). A = Attributable (who generated/modified data — identified by signature/initials). L = Legible (readable, permanent, not erasable). C = Contemporaneous (recorded at the time of the activity, not retroactively). O = Original (first recording, or verified true copy). A = Accurate (truthful, error-free). Extended: ALCOA+ adds Complete, Consistent, Enduring, and Available. Data integrity violations are one of the most common FDA warning letter findings.